Fiche publication
Date publication
décembre 2024
Journal
Immuno-oncology technology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr DAVIDSON Irwin
Tous les auteurs :
Willemsen M, Bulgarelli J, Chauhan SK, Lereim RR, Angeli D, Grisendi G, Krebbers G, Davidson I, Kyte JA, Guidoboni M, Luiten RM, Bakker WJ
Lien Pubmed
Résumé
Tumor heterogeneity is a hurdle to effective therapy, as illustrated by the 'mixed responses' frequently seen in immunotherapy-treated patients. Previously, AXL+ tumor cells were identified to be highly resistant to targeted therapy, whereas more differentiated MITF+ tumor cells do respond to RAF and MEK inhibitors.
Mots clés
AXL, DC vaccination, MITF, immune checkpoint, melanoma, tumor heterogeneity
Référence
Immunooncol Technol. 2024 12;24:101009
